ArticleJournal of personalized medicine2020
A Conformation Variant of p53 Combined with Machine Learning Identifies Alzheimer Disease in Preclinical and Prodromal Stages.
Article in Journal of personalized medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Systematic review: fluid biomarkers and machine learning methods to improve the diagnosis from mild cognitive impairment to Alzheimer's disease.Alzheimer's research & therapy · 2023Pooled it
- Machine Learning and Novel Biomarkers for the Diagnosis of Alzheimer's Disease.International journal of molecular sciences · 2021Pooled it
- Alzheimer's disease detection using a quantum deep neural network with Haralick feature extraction and simulated annealing optimization.PeerJ. Computer science · 2026Article
- A Scoping Review of Machine Learning-Based Prediction of Alzheimer's Disease Using Blood Biomarkers.Biomedical engineering and computational biology · 2026Review
- A visual mining analysis of middle meningeal embolization and other factors associated with recurrence requiring re-operation in subdural hematomas: a single-center series.Acta neurochirurgica · 2025Article
- Association Between U-p53AZ Blood Biomarker and White Matter Microstructure in Early Alzheimer's Disease: A Cross-Sectional Study Using AlzoSure® Predict.Health science reports · 2025Article
- Unraveling the genetic architecture of blood unfolded p-53 among non-demented elderlies: novel candidate genes for early Alzheimer's disease.BMC genomics · 2024Article
- Predicting Alzheimer's disease CSF core biomarkers: a multimodal Machine Learning approach.Frontiers in aging neuroscience · 2024Article
- Sting and p53 DNA repair pathways are compromised in Alzheimer's disease.Scientific reports · 2023Article
- The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology.International journal of molecular sciences · 2023Review
- The Clinical Application of Machine Learning-Based Models for Early Prediction of Hemorrhage in Trauma Intensive Care Units.Journal of personalized medicine · 2022Article
- The Road to Personalized Medicine in Alzheimer's Disease: The Use of Artificial Intelligence.Biomedicines · 2022Review
- Inflammation in the CNS: Understanding Various Aspects of the Pathogenesis of Alzheimer's Disease.Current Alzheimer research · 2022Review
- Post-translational Modifications of the p53 Protein and the Impact in Alzheimer's Disease: A Review of the Literature.Frontiers in aging neuroscience · 2022Review
- Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review.International journal of Alzheimer's disease · 2022Review
- Modified Low-Temperature Extraction Method for Isolation ofInternational journal of molecular sciences · 2021Article
- Variation in Phytochemical, Antioxidant and Volatile Composition of Pomelo Fruit (Plants (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 3 countries.
Funding
Abstract
Early diagnosis of Alzheimer's disease (AD) is a crucial starting point in disease management. Blood-based biomarkers could represent a considerable advantage in providing AD-risk information in primary care settings. Here, we report new data for a relatively unknown blood-based biomarker that holds promise for AD diagnosis. We evaluate a p53-misfolding conformation recognized by the antibody 2D3A8, also named Unfolded p53 (U-p53
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.